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Abstract
Background: Patient-reported outcomes (PRO) and clinical outcomes give a broad assessment of
relapsing–remitting multiple sclerosis (RRMS) disease.
Objective: The aim is to evaluate the effectiveness of delayed-release dimethyl fumarate (DMF) on
disease activity and PROs in patients with RRMS in the clinic.
Methods: PROTEC, a phase 4, open-label, 12-month observational study, assessed annualized relapse
rate (ARR), proportion of patients relapsed, and changes in PROs. Newly diagnosed and early MS (3.5
EDSS and 1 relapse in the prior year) patient subgroups were evaluated.
Results: Unadjusted ARR at 12 months post-DMF versus 12 months before DMF initiation was 75% lower
(0.161 vs. 0.643, p< 0.0001) overall (n¼ 1105) and 84%, 77%, and 71% lower in newly diagnosed, 3.5
EDSS, and 1 relapse subgroups, respectively. Overall, 88% of patients were relapse-free 12 months after
DMF initiation (84%, newly diagnosed; 88%, 3.5 EDSS; 88%, 1 relapse). PRO measures for fatigue,
treatment satisfaction, daily living, and work improved significantly over 12 months of DMF versus baseline.
Conclusion: At 12 months after versus 12 months before DMF initiation, ARR was significantly lower,
the majority of patients were relapse-free, and multiple PRO measures showed improvement (overall
and for subgroups), suggesting that DMF is effective based on clinical outcomes and from a patient
perspective.
Clinical trial: A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple
Sclerosis (MS) Disease Activity and Patient-Reported Outcomes (PROTEC), NCT01930708, https://
clinicaltrials.gov/ct2/show/NCT01930708.
Keywords: Dimethyl fumarate, multiple sclerosis, relapsing–remitting, patient-reported outcome meas-
ures, quality of life, treatment outcomes, activities of daily living
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Introduction
The debilitating character of multiple sclerosis (MS)
makes the assessment of quality of life (QoL) and
patient-reported outcomes (PROs) very important to
the patient, their families, and healthcare providers.
PROs are valuable tools for assessing disease states
and the effects of treatments from the patients’ per-
spective, allowing direct feedback on their well-
being and the impact of treatment on their health.
PROs can provide a broader overall assessment of
MS disease state and progression than clinical and
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neurological outcome measures such as annualized
relapse rate (ARR).1,2
Delayed-release dimethyl fumarate (DMF) is
approved as an oral treatment for relapsing and
relapsing–remitting MS (RRMS).3–5 As of 30 June
2019, >415,000 patients have been treated with
DMF, representing >780,000 patient-years of expo-
sure; 6335 patients (14,065 patient-years) were
from clinical trials (Biogen data on file). DMF dem-
onstrated sustained efficacy on clinical and neurora-
diological measures, and a favorable benefit-risk
profile, in patients with RRMS in two phase 3 stud-
ies, DEFINE (NCT00420212) and CONFIRM
(NCT00451451), and a phase 4 long-term extension
study ENDORSE (NCT00835770).6–8 PROs were
significantly improved with DMF treatment versus
placebo between integrated analysis of DEFINE and
CONFIRM, measured by EuroQol 5-Dimensions
visual analogue scale (EQ-5D VAS) and 36-Item
Short Form Health Survey,9 not measured in a clin-
ical setting. Patients with RRMS receiving DMF
experienced increased work productivity and
health-related QoL (HRQoL), measured by the
EuroQol-5D (EQ-5D), versus patients receiving
beta interferons or glatiramer acetate.10
Patients with RRMS have better long-term outcomes
when treated early with therapy controlling disease
activity.11 In post hoc analyses, efficacy in patients
with early MS, including newly diagnosed patients,
was consistent with the overall study populations.8,12
This analysis presents the primary outcome results
from PROTEC (NCT01930708), a 12-month obser-
vational study that evaluated DMF’s effectiveness
on disease activity and PROs in patients with
RRMS in a real-world clinical setting. An explorato-
ry endpoint subgroup analysis evaluated DMF’s
effectiveness in newly diagnosed and other patients
with early MS in PROTEC.
Materials and methods
Study design
PROTEC was a phase 4, open-label, single-arm,
observational, multicenter study conducted in
Europe and Canada from October 2013 to March
2016. Patients received the approved dosage of
DMF orally, 120 mg twice daily during the first
week and 240 mg twice daily thereafter. Relapses,
Expanded Disability Status Scale (EDSS), and
adverse events (AEs) were evaluated at scheduled
and unscheduled visits. PROs were assessed at
clinic visits scheduled at Baseline, 3, 6, and 12
months after DMF treatment initiation. The EDSS
scores13 ranged from 0.0 (normal) to 10.0 (death
due to MS). Patients were assessed for relapses
over the 12 months prior to DMF initiation.
Patients
Patient eligibility criteria included: age 18 years,
diagnosis of RRMS, and no prior treatment with
DMF or second-line MS therapies (e.g. natalizumab,
fingolimod, alemtuzumab). Exclusion criteria
included pregnancy or risk of pregnancy (unless
approved by Investigator), currently receiving other
RRMS therapies (e.g. interferon-b, glatiramer ace-
tate, or teriflunomide), hypersensitivity to DMF
active component, or current enrollment in other
clinical trials, other than Pregnancy Exposure
Registry or other non-conflicting studies. Patients
discontinued DMF if their lymphocyte counts were
< 0.5 109/l for 24 weeks.
Primary and secondary endpoints
The primary endpoint reported ARR 12 months after
DMF treatment in patients with RRMS. The second-
ary endpoints evaluated mean changes in PRO
scores from Baseline over 12 months; proportion
of patients with confirmed 24-week EDSS progres-
sion at 12 months after enrollment; ARR over 12
months before enrollment and at 12 months after
enrollment; proportion of patients relapsed at 12
months after enrollment; proportion of patients
with relapses associated with intravenous steroid
use; and proportion of patients who report taking
the prescribed DMF dose, overall percent adherence,
and reasons for not taking full dose over a 12-month
period. Additional outcomes included association
between health care resource utilization and disease
activity with PROs over a 12-month period, and
association between patient-reported adherence and
PROs over a 12-month period.
Patient-reported outcomes
For assessment of DMF impact on PROs, patients
completed the following instruments (language
translated). The PRIMUS-Activity Limitations ques-
tionnaire was not completed in Portugal due to lack
of available local translation. The Multiple Sclerosis
Impact Scale (MSIS-29) measures the physical (20
items) and psychological (nine items) impact of MS
on the patient’s previous 2-week day-to-day life.14,15
The Modified Fatigue Impact Scale 5-Item (MFIS-5)
consisted of five items describing how fatigue affect-
ed a person.16 Treatment Satisfaction Questionnaire
for Medication 14-item (TSQM-14) measures the
patient’s level of satisfaction/dissatisfaction with
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medication (14 items);17 only patients with previous
treatment were assessed for TSQM-14. EuroQol5D 5
level version (EQ-5D-5L) included two components:
the EQ-5D, a descriptive system of the patient’s
health state profile in five dimensions (mobility,
self-care, usual activities, pain/discomfort, and anx-
iety/depression), and the EQ-5D VAS, a quantitative
measure in which patients described their health on
that day on a scale from 0 to 100.18 For each patient,
EQ-5D scores were derived based on value sets for
England.18 Patient-reported Indices for Multiple
Sclerosis activity limitations (PRIMUS-Activity
Limitations) assessed the patient’s ability to perform
various activities of daily living during the previous
week without the use of aids (e.g. cane, walker, or
wheelchair) or assistance (15 items).19,20 Work
Productivity and Activity Impairment Multiple
Sclerosis Version (WPAI-MS) assessed employment
status and, during the previous 7 days, hours worked
(if employed), hours of missed work due to MS or
other reasons, effect on productivity due to MS
while working, and activity impairment attributable
to health problems (six items);21 WPAI-MS scores
are only reported for patients who were employed at
the time of PRO administration. Beck Depression
Inventory-Fast Screen (BDI-Fast Screen) evaluated
depression in patients with medical illness during the
prior 2 weeks (seven items).22
Early MS subgroups
Three early MS subgroups were pre-specified in the
statistical analysis plan as an exploratory endpoint:
(a) Newly diagnosed: diagnosed with MS 1 year
before study entry, naive to approved MS therapies;
(b) EDSS:23 baseline EDSS score 3.5; and (c)
Relapse: 1 relapse in the prior year.
Statistical analysis
An MS relapse was defined as new or recurrent neu-
rological symptoms not associated with fever or
infection, lasting 24 hours, accompanied by new
objective neurological findings upon examination by
the Investigator, followed by 30 days of stability or
improvement (new or recurrent neurological symp-
toms that occurred < 30 days following the onset of
a protocol-defined relapse were considered part of
the same relapse). ARR was calculated as the total
number of relapses in a period divided by the total
patient-years of exposure in that period. The primary
analyses for ARR, proportion of relapse, and PROs
were conducted in the primary analysis population,
comprising all eligible subjects, who provided
signed informed consent, enrolled, and took 1
dose of DMF. Ninety-five percent confidence inter-
nals (CIs) of unadjusted ARR and rate ratio were
estimated based on robust standard errors derived
from an unadjusted Poisson regression model using
the generalized estimating equation method. The
proportion of patients relapsed from Baseline to 12
months was estimated using the Kaplan–Meier
method based on time-to-first-relapse survival distri-
bution. If patients did not experience a relapse prior
to DMF discontinuation, they were censored on the
last date known to be in the study. Mean and median
change in PROs from Baseline to 12 months was
assessed using a Wilcoxon signed-rank test; only
patients with no missing data were included in the
tabulation. The frequency of patients with non-
missing data at each time point was presented. In
general, if there was < 15% of missing data at
any time point, data for that specific endpoint were
imputed and the primary analyses were based on
patients with non-missing data. If there was >15%
missing data at any time point, analysis was based on
a mixed-effects model.
The estimated proportion of patients with 24-week
confirmed disability progression was based on the
Kaplan–Meier product limit method, up to 52
weeks. Confirmed EDSS disability progression was
defined as 1.0 point increase in EDSS from a base-
line EDSS 1.0, or 1.5 point increase from a base-
line EDSS of 0, or 0.5 point increase from a
baseline EDSS 6 and confirmed at 6 months (154
days) after initial progression. Progression could start
at a scheduled assessment or relapse assessment
during the treatment period but could be confirmed
during either the treatment and/or follow-up 24-week
period. EDSS assessments during relapse assessments
were not used for confirmation. Patients were cen-
sored at the earliest of the last EDSS assessment
date during the treatment period or the last dose of
DMF if they did not have progression.
Analysis methods for the subgroups are consistent with
the primary analysis. For the association between
change from baseline of the PROs and resource utili-
zation (visit with neurologist: Yes/No) and treatment
adherence (80% vs. < 80%), mixed-model repeat-
ed measures method was adjusted for baseline PRO
values, baseline EDSS (3.5 vs. >3.5), visit and visit
by the factor of interest interaction term in the model.
All analyses were performed using SASV
R
v9.2 or
higher (SAS Institute, Cary, NC, USA).
Standard protocol approvals, registrations, and
patient consents
The study was approved by central and local ethics
committees and conducted in accordance with
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International Conference on Harmonization
Guidelines for Good Clinical Practice and the
Declaration of Helsinki. All patients provided writ-
ten informed consent.
Results
Patients
A total of 1105 (1114 enrolled) patients were includ-
ed in the primary analysis population (Figure 1).
Most baseline characteristics were similar to the
phase 3 pivotal studies;6,7 however, there were nota-
ble differences for PROTEC (Table 1) versus the
combined DEFINE/CONFIRM populations24 for
relapses in the year before study enrollment (0.6
vs. 1.3) and percentage of patients with any prior
MS medication (77% vs. 48%). Median (min,
max) duration of DMF treatment was 12.0 (0.03,
16.3) months; the majority of patients (941/1106,
85%) remained on DMF treatment for >9 months.
Mean (SD) overall adherence (weeks with full pre-
scribed dose taken divided by the total 0 weeks
during follow-up) was 80 (21%); 16% of patients
did not take the full prescribed dose during the study
due to side effects.
ARR
Unadjusted ARR at 12 months after DMF treatment
initiation was 75% lower than for 12 months
before DMF initiation (0.161 vs. 0.643, p< 0.0001;
Figure 2); and 88% of patients were relapse-free
12 months after DMF initiation versus 48% at
12 months before DMF initiation. A total of 710
relapses were experienced in 579 patients in the
12 months prior to initiating DMF, versus 155 relap-
ses in 135 patients in the 12 months after treatment
with DMF. Based on Kaplan–Meier estimates, 88%
of patients were relapse-free 12 months after DMF
initiation. At 1 year following DMF initiation,
21 (1.9%) patients had 24-week confirmed disease
progression prevalence; the cumulative incidence
estimated proportion was 2.2% by Kaplan–Meier
analysis. Among patients who experienced a relapse
requiring IV steroid therapy, 97 (9%) experienced
one, 11 (1%) experienced two, and one (< 0.1%)
experienced three relapses. Median (min, max)
EDSS scores showed minor improvements from
Baseline, 2.0 (0.0, 7.0), to Month 12, 1.5 (0.0, 7.0),
p¼ 0.0136.
PROs
A total of 84% of patients treated with DMF com-
pleted the 12-month follow-up period. Overall,
patients generally demonstrated improvement
across several PRO measures compared with base-
line (Table 2). For MSIS-29, measuring the physical
and psychological impact of MS of the patient’s day-
to-day life, there was significant improvement in
mean (SD) scores between Baseline and Month 12
for physical: 22.8 (21.5) versus 18.3 (19.8), and psy-
chological: 34.8 (23.7) versus 25.6 (22.2),
p< 0.0001 for both comparisons. For MFIS-5,
assessing the effects of fatigue on physical, cogni-
tive, and psychosocial functioning, there was signif-
icant improvement in mean (SD) scores between
Baseline and Month 12, 8.2 (5.0) versus 6.2 (5.1),
p< 0.0001. Similarly, mean (SD) scores between
Baseline and Month 12 scores in several WPAI
measures improved, measuring impairment in work
and activities due to MS: overall work impairment in
the past 7 days, 23.7 (27.1) versus 19.1 (24.7),
p¼ 0.0081; activity impairment in the past 7 days,
28.5 (27.8) versus 22.8 (26.0), p< 0.0001.
Other PRO measures showed small but significant
functional differences in scores. TSQM-14 scores
(patient satisfaction with their current medication)
1 (<0.1%) patient was not eligible
1114 patients enrolled
Reasons for withdrawal:
 AEs: 129 (11.7%)
 Consent withdrawn: 18 (1.6%)
 Lost to follow-up: 8 (0.7%)
 Investigator decision: 7 (0.6%)
 Other: 19 (1.7%)
1105 patients eligible, received 
≥1 dose of DMF (analysis population)
925 (83.6%) patients
completed study
181 (16.4%) patients withdrew
1106 patients received ≥1 dose
of DMF (safety population)
Figure 1. Patient disposition for the PROTEC study is shown.
AE: adverse events, DMF: delayed-release DMF.
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improved significantly between Baseline and
Month 12 for the global score and its components:
TSQM-14 global score, 51.4 (22.5) versus 73.6
(21.0); effectiveness, 54.3 (21.7) versus 70.1
(24.7); side effects, 60.1 (30.6) versus 85.4 (19.4);
convenience, 52.4 (21.2) versus 85.5 (17.2),
p< 0.0001 for all comparisons. There were signifi-
cant improvements from Baseline to Month 12 for
EQ-5D, 0.8 (0.2) versus 0.9 (0.2); EQ-5D VAS, 74.1
(18.7) versus 79 (17.5); and BDI-FAST, assessing
depressive symptoms, 2.8 (3.2) versus 1.9 (3.0),
p< 0.0001 for all comparisons.
PRIMUS-Activity Limitations scores remained
stable between Baseline and Month 12, mean (SD)
3.1 (4.6) at Baseline versus 2.6 (4.3) at Month 12,
suggesting no significant change in patients’ ability
to perform various activities of daily living without
aids or assistance. There was no evidence of change
in PRO scores between Baseline and Month 12 for
patients who visited a neurologist and those who did
not. Similarly, there was no evidence of a change in
PRO scores between Baseline and Month 12 patients
with < 80% adherence versus 80% adherence.
Early MS and other subgroups: Relapses and PRO
The effectiveness of DMF in newly diagnosed
patients and different levels of disability was
analyzed by dividing the population into
subgroups. Among the patients who received 1
Table 1. Patient baseline characteristics.
Characteristic
Total
N¼ 1105
Newly
diagnosed
n¼ 184
EDSS 3.5
n¼ 978
Relapse 1
n¼ 993
Mean (SD) age, y 38.8 10.0 35 (10) 38 (10) 39 (10)
Age category, y, n (%)
18–19 17 (2) 6 (3) 16 (2) 14 (1)
20–29 202 (18) 63 (34) 199 (20) 164 (17)
30–39 367 (33) 60 (33) 338 (35) 329 (33)
40–49 363 (33) 39 (21) 311 (32) 338 (34)
50–59 124 (11) 13 (7) 93 (10) 118 (12)
60 32 (3) 3 (2) 21 (2) 30 (3)
Female, n (%) 805 (72) 116 (63) 704 (72) 718 (72)
Relapses in year before study enrolment, mean (SD) 0.6 (0. 7) 1.1 (0.7) 0.6 (0.7) 0.5 (0.5)
Time since most recent pre-study relapse, mean (SD), ya 4.7 (3.3) 4.1 (3.0) 4.8 (3.3) 5.1 (3.4)
Time since diagnosis of MS, mean (SD), y 6.6 (6.1) 0.4 (0.5) 6.0 (5.5) 6.9 (6.1)
EDSS score, median (range) 2.0 (0, 7.0) 1.6 (0, 6.5) 1.6 (0, 3.5) 2.0 (0.7)
Patients with any prior MS disease-modifying therapy
n (%)b,c
828 (75) 2 (1) 722 (74) 763 (77)
Interferon beta-1a 499 (45) 0 (0) 442 (46) 460 (45)
Glatiramer acetate 318 (28) 0 (0) 276 (29) 293 (29)
Interferon beta-1b 175 (16) 0 (0) 139 (15) 157 (15)
Median (min, max) time since last MS disease-
modifying therapy discontinuation, mo
0.57 (0.03, 363.2)
Reason for prior MS treatment discontinuation, n (%)d
Tolerability 556 (50) 0 (0) 495 (52) 519 (51)
Efficacy reasons 335 (30) 0 (0) 266 (28) 291 (29)
Safety 58 (5) 1 (50) 50 (5) 53 (5)
Other 167 (15) 1 (50) 145 (15) 156 (15)
Total are patients in the primary analysis population.
EDSS: Expanded Disability Status Scale; values represent mean (SD) unless stated otherwise.
Race was not reported in 1001 patients due to confidentiality reasons implemented during the study.
aBased on data from 583 patients.
bOnly MS therapies taken before the first dose date of DMF initiation were included; patients may have received >1 therapy for MS.
cMedications previously taken by >10% of patients are shown. Other medications taken by >1% of patients include azathioprine, interferon
beta, interferon, and teriflunomide.
dIf patients have >1 discontinuation reason for same MS therapy, only the last reason was used.
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dose of DMF, 184 were newly diagnosed, 978 in the
EDSS 3.5 subgroup, and 993 in the 1 relapse
subgroup. Similar to the overall population, ARR
at 12 months after DMF initiation was 84% lower
than ARR estimated for the 12 months before DMF
initiation in newly diagnosed patients, 77% in the
EDSS 3.5 subgroup, and 71% in the 1 relapse
subgroups, p< 0.0001 for all subgroup (Figure 2(b)).
Based on Kaplan–Meier estimates, the percentages
of patients relapse-free 12 months after DMF initia-
tion were 84.2% for newly diagnosed patients,
87.7% in the EDSS 3.5 subgroup, and 88.4% in
the 1 relapse subgroup.
Significant improvements in scores from baseline to
12 months were observed across all early MS
subgroups for MSIS-29, MFIS-5, EQ-5D, and EQ-
5D VAS (Table 3).
Safety
Overall, 914 (83%) patients experienced an
AE; serious AEs occurred in 41 (4%) patients
(Table 4). One death occurred due to an accident,
deemed unrelated to DMF treatment. A total of 126
(11%) patients discontinued DMF treatment due to
AEs. The most common treatment-related AEs lead-
ing to DMF discontinuation (1% of patients)
were abdominal pain (2%), diarrhea (1%), and vom-
iting (2%).
No cases of progressive multifocal leukoencephalop-
athy were reported. Mean absolute lymphocyte
counts at 12 months (1.26 109/l) remained above
0.0
0.2
0.4
0.6
0.8
(a)
(b)
12 months
before DMF initiation
12 months
after DMF initiation
Rate ratio (95% CI)a
0.25 (0.21–0.30)
p < 0.0001
U
na
dj
us
te
d 
AR
R
b  (
95
%
 C
I)a
0.64 
(0.60–0.69)
0.16 
(0.14–0.19)
75% lower
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
U
na
dj
us
te
d 
AR
R
 (9
5%
 C
I)
Newly diagnosed
(n = 184)
1.13
(1.04–1.23) 84%
lower
0.18
(0.13–0.26)
Rate ratio (95% CI)
0.16 (0.11–0.23)
0.64
(0.59–0.68)
77%
lower
0.15
(0.12–0.18)
Rate ratio (95% CI)
0.23 (0.19–0.28)
≤3.5 EDSS
 (n = 978)
≤1 Relapse
 (n = 993)
0.47
(0.44–0.50)
71%
lower
0.14
(0.11–0.17)
Rate ratio (95% CI)
0.29 (0.24–0.35)
12 months after DMF initiation
12 months before DMF initiation
Figure 2. ARR at 12 months before and after DMF initiation for (A) all patients and (B) early MS subgroups.
aBased on empirical (robust) SE from a generalized estimating equation using an unadjusted Poisson regression model.
bARR was calculated as the total number of relapses that occurred during that period of time for all patients, divided by
the total number of patient-years followed in that period.
Subgroups are defined as: EDSS¼ baseline EDSS score 3.5; Relapse¼1 relapse in the prior year.
DMF: delayed-release DMF.
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Table 2. Mean change in PROs from baseline to 12 months.
Measure Description Component
Mean (SD) change from baseline to
Month 12
Improved Stable Worsened p-value
MSIS-29a 20 items assess physical impact
of MS in terms of mobility
and self-care
Physical impact
n¼ 868
þ
–3.0 (14.1)
<0.0001
9 items assess psychological
impact of MS
Psychological
impact
n¼ 860
þ
–8.0 (18.6)
<0.0001
MFIS-5b 5 items assess how fatigue
impacts patients’ lives
n¼ 867 þ
–1.7 (3.8)
<0.0001
TSQM-14c 14 items assess patient treatment
satisfaction
Effectiveness
n¼ 492
þ
14.4 (29.5)
<0.0001
Side effects
n¼ 500
þ
25.4 (31.4)
<0.0001
Convenience
n¼ 505
þ
33.4 (25.7)
<0.0001
Global score
n¼ 511
þ
21.8 (26.9)
<0.0001
EQ-5D-5Ld 5 items assess mobility, self-
care, usual activities, pain and
discomfort, anxiety and
depression
EQ-5D
n¼ 792
þ
0.02 (0.1)
<0.0001
EQ-5D VAS
n¼ 803
þ
3.7 (15.9)
<0.0001
PRIMUS
activity
limitationse
15 items assess activities of
daily living
n¼ 545 
–0.14 (3.2)
0.2134
WPAI-MSf 6 items assess the number of
work hours missed, impact on
productivity, and daily activi-
ties during past 7 days
Work impairmentf
n¼ 327
þ
–2.2 (19.5)
0.008
Activity impairment
n¼ 851
þ
–4.2 (22.3)
<0.0001
BDI-Fast
Screeng
7 items assess depression during
the past 2 weeks
n¼ 854 þ
–0.8 (2.5)
<0.0001
EDSSh Assesses disease progression n¼ 940 
–0.05 (0.65)
0.0136
BDI-Fast Screen: Beck Depression Inventory-Fast Screen; EDSS: Expanded Disability Status Scale; EQ-5D-5L: EuroQol-5D 5-level version;
MFIS-5: Modified Fatigue Impact Scale 5-item version; MSIS-29, Multiple Sclerosis Impact Scale; PRIMUS: Patient-Reported Indices for
Multiple Sclerosis; PRO: patient-reported outcome; TSQM-14: Treatment Satisfaction Questionnaire for Medication; WPAI-MS: Work
Productivity and Activity Impairment for Multiple Sclerosis.
Mean change in PROs from baseline to 12 months was assessed using a Wilcoxon signed-rank test.
aLower score indicates better outcome; range, 0–100 (scores were transformed).
bLower score indicates improved functioning; range, 0–20.
cHigher score indicates greater satisfaction; range, 0–100; only patients with previous treatment were assessed.
dHigher score indicates better health; range, 0–100.
eHigher score indicates better outcome; range, 0–30.
fHigher score indicates higher impairment and lower productivity; scores are only reported for patients who were employed at the time of PRO
administration.
gLower score indicates less severe depressive symptoms; range, 0–21.
hLower score indicates less severe disability symptoms; range, 0–10.
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the lower limit of normal (0.91 109/l) (Table 5),
consistent with trial data.6,7 Of the 400 patients with
2 post-baseline lymphocyte assessments, 44 (11%)
had moderate, persistent lymphopenia (2 consecu-
tive lymphocyte levels of < 0.8 109/l 180 days
apart), and four (1%) had severe, persistent lympho-
penia (two consecutive lymphocyte levels of
< 0.5 109/l 180 days apart).
Discussion
The results reported are consistent with DMF effec-
tiveness data from other real-world phase 4 studies
(RESPOND; NCT01903291),25 supporting the find-
ings from phase 3 studies of DMF.6,7 Unadjusted
ARR at 12 months after DMF treatment initiation
was significantly lower compared with 12 months
before DMF initiation. The majority of patients
were relapse-free 12 months after DMF initiation.
Safety and tolerability were consistent with the
known safety profile of DMF.3,4,6,7,24 Lymphocyte
counts were similar to those reported in pivotal clin-
ical trials and clinical practice.6,7,26–28 Statistically
significant improvements from baseline to 12
months were observed for the majority of PROs,
indicating that DMF is an effective MS treatment
from a patient perspective as well as based on clas-
sical clinical outcomes.
Clinical significance of PROs scores
In patients with MS and other chronic diseases, a
widely used threshold for discrimination of mean-
ingful change in HRQoL is 1/2 SD change in PRO
score over 1 year.29 In a population of patients with
RRMS, a 7.50 point worsening was determined to
be a practical threshold for identifying a clinically
significant change in the physical impact of MS
using the MSIS-29 physical score.30 The threshold
Table 3. Change in PROs from baseline to 12 months in early MS subgroups.
Measure Description Component
Newly diagnosed
(n¼ 184)
EDSS 3.5
(n¼ 978)
Relapse 1
(n¼ 993)
MSIS-29a 20 items assess physical
impact of MS in terms
of mobility and self-care
Physical
impact
þ
–3.1 (14.8)
þ
–2.7 (13.4)
þ
–3.2 (14.2)
9 items assess psycholog-
ical impact of MS
Psychological
impact
þ
–9.1 (16.9)
þ
–8.0 (18.2)
þ
–8.1 (18.5)
MFIS-5b 5 items assess how fatigue
impacts patients’ lives
þ
–1.6 (3.5)
þ
–1.7 (3.7)
þ
–1.7 (3.8)
EQ-5D VASc 5 items assess mobility,
self-care, usual activi-
ties, pain and discom-
fort, anxiety and
depression
þ
4.1 (13.7)
þ
3.6 (15.1)
þ
3.7 (15.9)
EDSS: Expanded Disability Status Scale; EQ-5D VAS: EQ-5D visual analogue scale; MFIS-5: Modified Fatigue
Impact Scale 5-item version; MSIS-29: Multiple Sclerosis Impact Scale; PRO: patient-reported outcome.
þ¼Statistically significant improvement; ¼ no statistically significant change; –¼ statistically significant
worsening.
aLower score indicates better outcome; range, 0–100 (scores were transformed).
bLower score indicates improved functioning; range, 0–20.
cHigher score indicates better health; range, 0–100.
Table 4. Summary of adverse events.
AE, n (%)
Total
n¼ 1106
Any AE 914 (83)
Most common AEs in 10% patients
Flushing 477 (43)
Diarrhea 172 (16)
Abdominal pain upper 120 (11)
Abdominal pain 115 (10)
Any SAE 41 (4)
Most frequently occurring SAEs in 2 patients
Fall 4 (<1)
Lymphopenia 3 (<1)
Breast cancer 2 (<1)
MS relapse 2 (<1)
AE: adverse event; SAE: serious adverse event.
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for worsening was defined as < –0.074 points for
EQ-5D31 and < –5.5 points for EQ-5D VAS,32
although these thresholds were not calculated in
patients with MS. In this analysis, the mean
change was –3.0 for MSIS-29 physical score, 0.02
for EQ-5D, and 3.7 for EQ-5D VAS: statistically
significant, although they may not be meaningful
clinical changes based on criteria described in pre-
vious studies. By the 1/2 SD rule, MFIS-5 (mean
–1.7; SD 3.8), TSQM-14 side effects, TSQM-14
convenience, and TSQM-14 global score reached
clinically significant change.
Early MS treatment has been associated with a
reduction in disease progression.33,34 When consid-
ering the optimal treatment for reducing disease pro-
gression risk in patients with early MS, relapses,
MRI lesions, disability progression, and brain
volume loss are four key measures of disease activ-
ity.35 For treatment-naı¨ve patients, IFN-b, glatiramer
acetate, teriflunomide, and DMF, followed by fingo-
limod, natalizumab, and alemtuzumab, have been
suggested in patients with breakthrough disease
activity.35 ARR and PRO results for the newly diag-
nosed subgroup and the subgroups with EDSS 3.5
or relapse 1 in the prior year were similar to the
overall group, indicating DMF is effective in a broad
range of patients.
The results and interpretations are subject to several
limitations common to real-world studies, including
the observational nature of the study, short duration
of follow-up time on DMF, and lack of active com-
parators. Potential bias arises due to regression to
the mean because the majority of patients enrolled
had previous experience with disease-modifying
therapies (DMTs) for MS. Therefore, familiarity to
compliance with treatment and dosage requirements
impact the generalizability of results for treatment-
naı¨ve or less adherent patients. Due to the real-world
nature of the study, eligibility criteria did not restrict
participation to patients with 1 relapse over the
12-month period prior to study entry, as in
DEFINE and CONFIRM, rendering it possible that
patients in this study had a less severe progression of
MS at enrollment. Therefore, these patients may
have exhibited lower risk possibly resulting in
lower incidence of relapse over the study period,
regardless of treatment. The study design may
impede researchers dictating when PRO assessments
are completed relative to relapses. PRO assessments
obtained shortly after relapse have a greater risk of
being affected by the relapse compared with PROs
obtained with no recent relapse, although compari-
sons of PRO outcomes in patients with or without
relapses during the study found either a marginal
difference or no difference in the change from
Baseline to Month 12. Missing data from patient-
reported measures is a limitation of real-world stud-
ies; however, mitigating the risk of missing data
impacting study results, the proportion of missing
data was described and accounted for throughout
the statistical analyses. Unfortunately, the influence
of patients “not missing at random” may introduce
bias in both the estimate and variance for which the
sensitivity analysis cannot account. To minimize
potential bias due to methods of data collection,
case report forms were carefully designed, with
clear instructions and training provided to site
staff; furthermore, mitigations were carried out if
data entry concerns were identified. Finally, the
11.7% of patients who discontinued due to AEs
Table 5. Lower lymphocyte counts.
Total
Mean (SD) lymphocyte counts, 109/l 1.26 (0.55)
Baseline, n¼ 1038 1.93 (0.61)
Month 12, n¼ 897 1.26 (0.55)
0.8 – <0.91 (LLN), n/N (%)a 69/831 (8)
0.5 – <0.8, n/N (%)a 133/831 (16)
<0.5, n/N (%)a 17/831 (2)
Patients with 2 post-baseline lymphocyte assessments, n 400
Moderate, persistent lymphopeniab, n 44
Severe, persistent lymphopeniac, n 4
ALC: absolute lymphocyte count; LLN: lower limit of normal.
aFor patients with at least 1 baseline assessment >LLN.
bALC of at least 2 consecutive lymphocyte levels of <0.8 109/L 180 days apart.
cALC of at least 2 consecutive lymphocyte levels of <0.5 109/L 180 days apart.
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may introduce possible confounding or bias in the
QoL measures, given the symptomatic nature of
some AEs and their impact of QoL outcomes.
Comparing treatment-satisfaction scores between pre-
viously discontinued drugs with treatment-satisfaction
scores in drugs not discontinued for 12 months
could be biased in favor of DMF purely because of
patient selection. Sensitivity analyses were performed
for primary and secondary endpoints using patient
populations who completed the full study period
(completer population), in order to evaluate potential
effects of early study withdrawal on analytic results.
Results were similar between the completer and anal-
ysis populations. Also, since the exclusions criteria
were only based on last DMT, the assessment may
be limited if patients were on multiple DMTs and
omitting the type or strength of DMT.
Conclusions
Overall, the results suggest that DMF may offer an
effective treatment option for patients with RRMS,
both from a clinical perspective and based on
patients’ satisfaction with DMF treatment in relation
to their personal quality of life, health status, and
physical abilities.
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